Cooperative Agreement 2545371
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $1.3M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Birmingham, AL 35203, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
- This STTR Phase I Project Grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, is funding the development of a novel tissue-engineered platform for cancer modeling and drug screening. The $275,000 award to Vivosphere LLC will be used to create a more physiologically relevant and versatile high-throughput screening model that can improve the translation rate between preclinical and clinical testing of anti-cancer...
- The National Science Foundation awarded Opal Therapeutics Inc. a $1.25 million cooperative agreement on August 1, 2026, to develop scalable platforms for translational research and therapeutic screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The project pursues three primary objectives: expanding a current biobank with increased metadata acquisition; automating culture and imaging workflows using proprietary media formulations to increase throughput and...
- Federal Cooperative Agreement Summary Award: NSF SBIR Phase II: nCapsule Personalized Cancer Screening for Colorectal Cancer Treatment Regimens Funding Agency: National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Awardee: Encapsulate Inc., Farmington, Connecticut Award Amount: $1,213,619 | Award Date: June 15, 2025 | Completion Date: May 31, 2027 Encapsulate Inc. is developing an integrated precision oncology platform that combines microfluidics,...
- The National Science Foundation awarded Empiri, Inc. a Cooperative Agreement valued at $1,249,794 on July 1, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an automated tumor slice culture instrument that measures cancer patients' drug treatment response. The project refines an automated tissue slicer and handler (ATSH) prototyped in Phase I, with objectives including scaling of sample preparation, refinement and expansion of ATSH design and...
- The National Science Foundation awarded Beken Bio, Inc. a $1,249,464 cooperative agreement on August 1, 2026, under the SBIR Phase II program to develop a liquid biopsy diagnostic tool that detects cancer through extracellular vesicle biomarkers in blood samples. The recipient will conduct a prospective, blinded clinical study of approximately 300 patients undergoing surgery to validate a diagnostic test that measures cancer signals carried by extracellular vesicles (EVs)—tiny particles released...
- The National Science Foundation awarded Rumedical Nova LIMITED Liability Company $305,000 on July 15, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to design and validate a compact chip-based platform for detecting lung cancer biomarkers in blood serum with high sensitivity and speed. The research will focus on developing an innovative nanoscale sensing element capable of recognizing disease signals at extremely low concentrations in a rapid, sensitive, and...
- This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...
- Federal Cooperative Agreement Summary Nexgen Cancer Detection LLC received a $1.25M Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded June 15, 2025, with completion targeted for May 31, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project to develop and validate an enriched cancer DNA detection technology for improved cancer diagnostics from blood samples. The...
- This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023. The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo ineffective...